Progyny, Inc. Provides Business Update and Announces Details for Its Second Quarter 2025 Results Report
Second Quarter Results Anticipated to be Slightly Above Previously Provided Financial Guidance
NEW YORK, July 08, 2025 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY) ('Progyny' or the 'Company'), a global leader in women's health and family building solutions, today announced that it has entered into a revolving credit facility (the 'revolver' or the 'facility') which makes available to the Company up to $200 million in aggregate revolving credit commitments, which the Company can utilize for revolving credit borrowings, subject to customary borrowing conditions, until maturity on July 1, 2030. The facility is expected to enhance the Company's operational and financial flexibility beyond its current ability to generate significant cash flow.
'At this stage of our growth, entering into a facility is an appropriate next step to further enhance our strong financial profile and extend our market leadership, and with the favorable market conditions, we felt this was an opportune time for us to transact,' said Pete Anevski, Chief Executive Officer of Progyny.
The revolver is undrawn, and the Company has no planned use for the facility at this time. The Company's capital priorities, which include the evaluation of stock repurchases, the expansion of its product portfolio, investments in new distribution channels, and select acquisitions, remain unchanged.
The Company also announced today that it expects its financial results for the quarterly period ending June 30, 2025, to be slightly better than the guidance ranges it provided during its first quarter earnings call.
'As the second quarter progressed, we were pleased to see that member activity has paced favorably as compared to our guidance,' continued Anevski. 'Accordingly, we now expect second quarter results for revenue, Adjusted net income and Adjusted EBITDA to be slightly above the ranges that we provided in May.'
The company will report its financial results for the quarterly period ended June 30, 2025, after the close of the market on Thursday, August 7, 2025.
The company will host a conference call at 4:45 p.m. Eastern Time (1:45 p.m. Pacific Time) and issue a press release regarding its financial results prior to the start of the call.
Interested participants in the United States may access the conference call by dialing 1.866.825.7331 and using the passcode 265484. International participants may access the call by dialing 1.973.413.6106 and using the same passcode. An audio replay of the call will be available through Thursday, August 14, 2025, and may be accessed by dialing 1.800.332.6854 (U.S. participants) or 1.973.528.0005 (international participants) with the passcode 265484.
A live webcast and archive of the call will be available from the Events and Presentations section of the company's website at http://investors.progyny.com.
About Progyny
Progyny (Nasdaq: PGNY) is a global leader in women's health and family building solutions, trusted by the nation's leading employers, health plans and benefit purchasers. We envision a world where everyone can realize their dreams of family and ideal health. Our outcomes prove that comprehensive, inclusive and intentionally designed solutions simultaneously benefit employers, patients, and physicians.
Our benefits solution empowers patients with concierge support, coaching, education, and digital tools; provides access to a premier network of fertility and women's health specialists who use the latest science and technologies; drives optimal clinical outcomes; and reduces healthcare costs.
Headquartered in New York City, Progyny has been recognized for its leadership and growth as a TIME100 Most Influential Company, CNBC Disruptor 50, Modern Healthcare's Best Places to Work in Healthcare, Forbes' Best Employers, Financial Times Fastest Growing Companies, INC. 5000, INC. Power Partners and Crain's Fast 50 for NYC. For more information, visit www.progyny.com.
Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements contained in this press release other than statements of historical fact, including, without limitation, statements regarding our financial outlook for the second quarter and full year 2025, including the impact of our sales season and client launches; our anticipated number of clients and covered lives for 2025; our expected utilization rates and mix; the demand for our solutions; our expectations for our selling season for 2026 launches; our positioning to successfully manage economic uncertainty on our business; the timing of client decisions; our ability to retain existing clients and acquire new clients; and our business strategy, plans, goals and expectations concerning our market position, future operations, and other financial and operating information. The words 'anticipates,' 'assumes,' 'believe,' 'contemplate,' 'continues, ' 'could,' 'estimates,' 'expects,' 'future,' 'intends,' 'may,' 'plans,' 'predict,' 'potential,' 'project,' 'seeks,' 'should,' 'target,' 'will,' and the negative of these or similar expressions and phrases are intended to identify forward-looking statements, though not all forward-looking statements use these words or expressions.
Forward-looking statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward- looking statements. These risks include, without limitation, failure to meet our publicly announced guidance or other expectations about our business; competition in the market in which we operate; our history of operating losses and ability to sustain profitability; unfavorable conditions in our industry or the United States economy; our limited operating history and the difficulty in predicting our future results of operations; our ability to attract and retain clients and increase the adoption of services within our client base; the loss of any of our largest client accounts; changes in the technology industry; changes or developments in the health insurance market; negative publicity in the health benefits industry; lags, failures or security breaches in our computer systems or those of our vendors; a significant change in the utilization of our solutions; our ability to offer high-quality support; positive references from our existing clients; our ability to develop and expand our marketing and sales capabilities; the rate of growth of our future revenue; the accuracy of the estimates and assumptions we use to determine the size of target markets; our ability to successfully manage our growth; reductions in employee benefits spending; seasonal fluctuations in our sales; the adoption of new solutions and services by our clients or members; our ability to innovate and develop new offerings; our ability to adapt and respond to the changing medical landscape, regulations, and client needs, requirements or preferences; our ability to maintain and enhance our brand; our ability to attract and retain members of our management team, key employees, or other qualified personnel; risks related to any litigation against us; our ability to maintain our Center of Excellence network of healthcare providers; our strategic relationships with and monitoring of third parties; our ability to maintain our pharmacy distribution network if there is a disruption to our network or its associated supply chains; our relationship with key pharmacy program partners or any decline in rebates provided by them; our ability to maintain our relationships with benefits consultants; exposure to credit risk from our members; risks related to government regulation; risks related to our business with government entities; our ability to protect our intellectual property rights; risks related to acquisitions, strategic investments, or partnerships; federal tax reform and changes to our effective tax rate; the imposition of state and local state taxes; our ability to utilize a portion of our net operating loss or research tax credit carryforwards; our ability to develop or maintain effective internal control over financial reporting; and our ability to adapt and respond to the changing SEC or stakeholder expectations regarding environmental, social and governance practices. For a detailed discussion of these and other risk factors, please refer to our filings with the Securities and Exchange Commission (the 'SEC'), including in the section entitled 'Risk Factors' in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024, and subsequent reports that we file with the SEC, which are available at http://investors.progyny.com and on the SEC's website at https://www.sec.gov.
Forward-looking statements represent our management's beliefs and assumptions only as of the date of this press release. Our actual future results could differ materially from what we expect. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons.
Non-GAAP Financial Measures
In addition to disclosing financial measures prepared in accordance with U.S. generally accepted accounting principles ('GAAP'), this press release includes the non-GAAP financial measure Adjusted EBITDA. Adjusted EBITDA is a supplemental financial measure that is not required by, or presented in accordance with, GAAP. We believe that this non-GAAP measure, when taken together with our GAAP financial results, provides meaningful supplemental information regarding our operating performance and facilitates internal comparisons of our historical operating performance on a more consistent basis by excluding certain items that may not be indicative of our business, results of operations or outlook. In particular, we believe that the use of Adjusted EBITDA is helpful to our investors as it is used by management in assessing the health of our business, determining incentive compensation, evaluating our operating performance, and for internal planning and forecasting purposes.
Adjusted EBITDA is presented for supplemental informational purposes only, has limitations as an analytical tool and should not be considered in isolation or as a substitute for financial information presented in accordance with GAAP. Some of the limitations of Adjusted EBITDA include: (1) it does not properly reflect capital commitments to be paid in the future; (2) although depreciation and amortization are non-cash charges, the underlying assets may need to be replaced and Adjusted EBITDA does not reflect these capital expenditures; (3) it does not consider the impact of stock-based compensation expense; (4) it does not reflect other non-operating income and expenses, including interest and other income, net; and (5) it does not reflect tax payments that may represent a reduction in cash available to us. In addition, Adjusted EBITDA may not be comparable to similarly titled measures of other companies because they may not calculate such measures in the same manner as we calculate Adjusted EBITDA, limiting its usefulness as a comparative measure. Because of these limitations, when evaluating our performance, you should consider Adjusted EBITDA alongside other financial performance measures, including our net income and our other GAAP results.
We calculate Adjusted EBITDA as net income, adjusted to exclude depreciation and amortization; stock-based compensation expense; interest and other income, net; and provision for income taxes.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
8 minutes ago
- Globe and Mail
These 3 Dividend Stocks Have Yields Above 5%, Plus They Raise Their Payouts Every Year
Key Points Realty Income is a real estate investment trust that has raised its dividend payout 131 times since 1994. Verizon's a reliable telecom provider that offers a yield above 6% at recent prices. Pfizer's heading for a rough patch that could last a few years, but it has the means to overcome upcoming challenges. 10 stocks we like better than Realty Income › If you're looking to boost your passive income stream with dividend-paying stocks, there's a tough dilemma that we all face. Stocks that offer high yields generally do so because their dividend payouts aren't growing very fast or at all. On the other hand, companies that raise their payouts quickly tend to offer unattractive yields. Most, but not all, dividend payers can be easily sorted into the low or high yield camp with corresponding expectations for the growth of their payouts. Realty Income (NYSE: O), Verizon (NYSE: VZ), and Pfizer (NYSE: PFE) stand out right now because they have been raising the payments they send shareholders for over a decade, and they offer yields above 5% at recent prices. 1. Realty Income Shares of Realty Income have been delivering monthly dividend payments for over 50 years. Unfortunately, Treasury yields that have risen in recent years make reliable dividend stocks less attractive. Shares of this ultrareliable dividend growth stock are down about 22% from a peak they reached over three years ago. Realty Income is a real estate investment trust (REIT) that employs net leases, which make its tenants responsible for all the variable costs that come with owning its buildings. Net leases lead to predictable cash flows. Since becoming a publicly traded company in 1994, the company has raised its dividend 131 times, or nearly every quarter. A declining stock price amid steadily rising payouts means Realty Income stock offers an above-average yield of 5.5% at recent prices. Total distributions during the second quarter were 3.7% higher year over year, and continued growth at a similar pace or faster seems highly likely. At the end of June, 98.6% of Realty Income's 15,606 properties were occupied, with a weighted average of nine years remaining on their lease terms. With rent escalators written into its long-term leases, investors can rely on this REIT to deliver steadily growing cash flows for many years to come. 2. Verizon Shares of the largest member of America's three-way telecom oligopoly last reached an all-time high in late 2019. The stock is down about 28% from its previous peak, but its quarterly dividend payment keeps on growing. Last September, the company raised its payout for the 18th consecutive year. At recent prices, it offers a 6.1% yield. Selling wireless services isn't the growth driver it used to be, but the business is still moving in the right direction. Second-quarter wireless service revenue rose 2.2% year over year to $20.9 billion. With help from a broadband internet business that added 632,000 net new subscribers in the first half of the year, total second-quarter revenue rose 5.2% year over year. In July, Verizon raised its free cash flow forecast for 2025 to a range between $19.5 billion and $20.5 billion. Dividends paid in the first half of 2025 work out to an annualized $11.4 billion. In other words, the company has the means to maintain its dividend payout and significantly reduce debt at the same time. 3. Pfizer Shares of Pfizer are down by about 59% from a peak they set in 2021, when it seemed its COVID-19 vaccine and antiviral treatment could continue producing record-breaking sales figures. These days, investors have been fleeing the stock in fear of upcoming losses resulting from expiring drug patents. Pfizer has raised its payout every year since 2009. At recent prices, the pharmaceutical giant offers a big 6.8% dividend yield that could be on firmer footing than you might imagine. Earlier this year, CEO Albert Bourla warned investors that a loss of market exclusivity wave could reduce annual revenues by $17 billion to $18 billion, beginning in 2026 and ending in 2028. Drug patent expirations are a fact of life that all established drugmakers deal with year in and year out. Pfizer's about to experience a particularly rough patch, but it isn't something the company hasn't already prepared for. For example, in 2023, it acquired cancer drug developer Seagen for $43 billion in cash. By 2030, assets acquired from Seagen and others are expected to generate more than $20 billion in annual sales. It's a long way from guaranteed, but there's a good chance that new products can allow Pfizer to maintain its dividend-raising streak in the decade ahead. Adding some of the high-yielding shares to a diversified portfolio now looks like a smart move for folks who want to pump up their passive income stream. Should you invest $1,000 in Realty Income right now? Before you buy stock in Realty Income, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Realty Income wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $668,155!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,106,071!* Now, it's worth noting Stock Advisor's total average return is 1,070% — a market-crushing outperformance compared to 184% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 13, 2025
Globe and Mail
17 minutes ago
- Globe and Mail
Is Solana a Millionaire-Maker?
Key Points Solana's price has pulled back from its all-time high earlier this year. New ETFs, fresh partnerships, and network upgrades could drive its price higher. But it still faces stiff competition from Ethereum and other developer-driven networks. 10 stocks we like better than Solana › Solana (CRYPTO: SOL), the native cryptocurrency of the Solana blockchain, turned a lot of its early investors into millionaires. It was officially launched in 2020, but it previously sold some of its tokens at just $0.04 in a seed sale in 2018. Solana now trades at about $185, so a $1,000 investment in that seed sale would be worth almost $5 million today. However, Solana trades more than 35% below its all-time high from this January. Let's see why this cryptocurrency initially rallied, why it pulled back, and whether it can churn a fresh $1,000 investment into $1 million again during the next few years. Why did Solana's price skyrocket? Unlike Bitcoin (CRYPTO: BTC), which is mined with the energy-intensive proof-of-work (PoW) consensus mechanism, Solana uses the more energy-efficient proof-of-stake (PoS) mechanism to validate its transactions. Therefore, Solana's tokens can only be staked (locked up for interest-like rewards) instead of mined. So, while Bitcoin is a deflationary token with a set maximum supply, Solana is an inflationary one with no maximum supply. That makes Solana, which has a circulating supply of nearly 540 million tokens, difficult to value by its scarcity. Instead, it's mainly valued by the growth of its developer ecosystem. As a PoS blockchain, Solana supports smart contracts, which are used to create decentralized apps (dApps), non-fungible tokens (NFTs), and other tokenized assets. Its Layer-1 (L1) blockchain, which has a real-world top speed of about 4,000 transactions per second (TPS), is much faster than other L1 PoS blockchains, such as Ethereum (CRYPTO: ETH) and Cardano (CRYPTO: ADA), which have comparable maximum speeds of about 15 and 250 TPS, respectively. Solana achieves those higher speeds by integrating its own proof-of-history (PoH) validation mechanism (which timestamps transactions before they're validated) into its PoS blockchain. Those higher speeds drew in more developers and investors who expected it to disrupt Ethereum and other developer-oriented PoS blockchains. That enthusiasm, along with expectations for lower interest rates and more relaxed regulations for cryptocurrencies, drove Solana's price to its record high earlier this year. Solana's expansion of its own ecosystem with its digital payments platform Solana Pay, support for stablecoins, and the launch of its own Android phone fanned those flames. Why did Solana's price pull back? Solana has some obvious strengths, but it also has three glaring weaknesses. First, its L1 blockchain often struggles with network congestion, outages, and security issues. Those problems could outweigh the advantages of its faster transactions. Second, Solana isn't natively cross-compatible with other blockchains, like Ethereum, and its main developer languages (Rust and C) have a steeper learning curve than Ethereum's Solidity. That's why Solana still attracts a much smaller pool of developers than Ethereum. Lastly, its competitors are using more Layer-2 (L2) solutions, which bundle together multiple transactions and process them off-chain at higher speeds to ease the congestion on their L1 blockchains. For example, Ethereum's L2s "rollups" can achieve real-world speeds of up to 4,000 TPS, while Cardano's L2 "hydra heads" can each achieve real-world speeds of up to 1,000 TPS. Those solutions could lure more developers away from Solana's speedy but volatile network. Could it generate more millionaire-making gains? Solana needs to address those issues, but a few major catalysts could be on the horizon. First, new exchange-traded funds (ETFs) for Solana could stabilize its price while drawing in more retail and institutional investors. The REX-Osprey Solana + Staking ETF (NYSEMKT: SSK) already started trading in the U.S. last month as the first Solana ETF. Instead of being directly approved by the Securities and Exchange Commission (SEC), that ETF was launched after the SEC simply didn't object to its filing. Several filings for Solana ETFs from bigger firms -- including VanEck, 21Shares, and Franklin Templeton -- are still being reviewed by the SEC, but they could be launched in the near future. As interest rates decline, more investors should shift back toward cryptocurrencies and other riskier investments. Solana's high staking yield of 7% to 8% could also attract more yield-seeking investors than Ethereum, which has a staking yield of 3% to 4%. Solana's expansion of its ecosystem with more digital payment partners, which already include Visa (NYSE: V) and Shopify (NASDAQ: SHOP), could attract more developers. Its future network upgrades should also reduce its congestion issues and fortify its security features. But for a $1,000 investment to grow into $1 million, its price would need to skyrocket 1,000-fold to $185,000 and boost its market cap from about $100 billion to $100 trillion. That would make it more valuable than gold, which has a market cap of $22.8 trillion; Bitcoin, which is worth $2.3 trillion; and Ethereum, which is valued at $530 billion. That doesn't seem like a realistic goal. So, while Solana might stabilize and rise in the future, it probably won't come close to replicating its previous millionaire-making gains. Should you invest $1,000 in Solana right now? Before you buy stock in Solana, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Solana wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $668,155!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,106,071!* Now, it's worth noting Stock Advisor's total average return is 1,070% — a market-crushing outperformance compared to 184% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 13, 2025 Leo Sun has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Bitcoin, Ethereum, Shopify, Solana, and Visa. The Motley Fool has a disclosure policy.
Globe and Mail
38 minutes ago
- Globe and Mail
Which Is the Better Choice for Investing $10,000 Right Now: Palantir or XRP (Ripple)?
Palantir should have tremendous growth prospects with its AI-powered software. XRP could soar if investors are allowed to buy cryptocurrencies in their 401(k) plans. Which asset is the better pick depends on your risk tolerance and investment horizon. 10 stocks we like better than Palantir Technologies › What's the best-performing S&P 500 stock so far in 2025? There's no contest. Palantir Technologies (NASDAQ: PLTR) has trounced all other contenders with a year-to-date gain of over 140%. There isn't an equivalent of the S&P 500 for cryptocurrencies. However, among digital currencies with a market cap of at least $100 billion, XRP (CRYPTO: XRP) (sometimes referred to as Ripple, which is the name of the company that popularized the cryptocurrency) is the clear winner with a year-to-date gain of around 60%. Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue » Stocks and cryptocurrencies are vastly different, yet they vie for the same pool of investors' hard-earned cash. Which is the better choice for investing $10,000 right now: Palantir or XRP? Image source: Getty Images. The case for Palantir Palantir describes what it does as making "products for human-driven analysis of real-world data." However, those products rely heavily on artificial intelligence (AI), including machine learning and generative AI. The company's initial focus was on providing software to governments (particularly intelligence and defense agencies), but it has expanded into commercial applications as well. Both of Palantir's core markets are booming. The company's U.S. commercial revenue skyrocketed 93% year over year in the second quarter of 2025 to $306 million. Its U.S. government revenue soared 53% year over year to $426 million. Palantir's overall revenue jumped 48% to a little over $1 billion. CEO Alex Karp wrote to shareholders recently that this growth rate is "nearly without precedent or comparison" for a business of Palantir's scale. He also stated, "This is still only the beginning of something much larger and, we believe, even more significant." He could be right. IDC projects that the global AI platform software market will grow by a compound annual growth rate of 40.6% through 2028 to $153 billion. Palantir outshines every software maker in the world with at least $1 billion in trailing-12-month revenue on the "Rule of 40" metric. This number combines a company's revenue growth and its profit margin. Palantir's "Rule of 40" score is 94%. Among the 25 global companies with the largest market caps, only Nvidia has a higher score. The case for XRP David Schwartz, Jed McCaleb, and Arthur Britto set out in 2011 to develop a digital asset that was specifically designed for payments and would be better than Bitcoin. They wound up creating the XRP Ledger, which uses XRP as its native currency. The three engineers launched a company to expand the blockchain platform they developed. After a couple of name changes, this company became Ripple. Today, XRP ranks as the third-largest cryptocurrency in the world with a market cap of over $180 billion. It's traded on more than 100 markets and exchanges. Roughly 59.3 billion XRP tokens are in circulation, with a total supply of nearly 100 billion tokens. XRP's growth prospects hinge on demand for the cryptocurrency outstripping supply. That hasn't been a problem so far -- and might not be going forward, either. For one thing, its developers' goal of building a better version of Bitcoin appears to have been achieved. XRP takes only three to five seconds to settle a payment, compared with 500 seconds for Bitcoin. It also boasts a much lower cost per transaction, is much more scalable, and consumes much less energy than Bitcoin. Demand could also soar thanks to President Trump's recently signed executive order directing the U.S. government to take steps to allow 401(k) plan investments in alternative assets, including cryptocurrencies. In addition, several investment management companies are scrambling to launch exchange-traded funds (ETFs) that own XRP. And the verdict is... Which of these assets is the better alternative for investing $10,000 right now? I think it depends on your risk tolerance and investment horizon. Both XRP and Palantir are risky. Like any cryptocurrency, XRP is only worth what investors think it's worth. Some would argue that it has no intrinsic value (although that's debatable). Palantir's risk level primarily comes from its valuation: The stock trades at 294 times forward earnings -- a nosebleed level. However, because of the company's growth prospects, I'd say it's less risky than XRP overall. That said, it wouldn't surprise me if XRP outperforms Palantir over the short term. The creation of new ETFs focusing on the cryptocurrency and the likelihood that investors will soon be able to buy those ETFs and perhaps buy XRP directly in their 401(k) accounts could provide major catalysts. What about over the long term? I think the nod goes to Palantir. The potential for AI to transform governments and businesses is massive. Still, other stocks offer better risk-reward propositions than Palantir, in my view. Should you invest $1,000 in Palantir Technologies right now? Before you buy stock in Palantir Technologies, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Palantir Technologies wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $668,155!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,106,071!* Now, it's worth noting Stock Advisor's total average return is 1,070% — a market-crushing outperformance compared to 184 % for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor . See the 10 stocks » *Stock Advisor returns as of August 13, 2025 Keith Speights has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Bitcoin, Nvidia, Palantir Technologies, and XRP. The Motley Fool has a disclosure policy. This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
